entecavir

In a Phase 1 clinical study conducted under clinical trial agreement in the United Kingdom and South Korea, three monthly injections at two dose levels of HepTcell peptides were given with and without IC31 adjuvant as add-on therapy to entecavir or tenofovir in patients with HBe antigen negative chronic infections.

We provide four medicine case studies, on lenalidomide, entecavir, erlotinib and sorafenib, to illustrate how concrete reform of SA's patent law can facilitate greater medicine access and equity between the public and private health sectors.

Hepatitis B is a significant worldwide health problem, which is treated with entecavir, a common nucleoside (deoxyguanosine) analog with various side effects, such as lactic acidosis, myalgia, azotemia, hypophosphatemia, headache, diarrhea, pancreatitis, and neuropathy, and, in rare cases, cutaneous drug eruption (3,4,5).

Patients between 18 and 70 years receiving oral antiviral agents (lamivudine, entecavir, or tenofovir disproxil fumarate) for a minimum duration of 3 years due to CHB were included.

The patent and licensing status of entecavir and tenofovir, two WHO-recommended medicines for HBV treatment, were examined using the Medicines Patent Pool MedsPaL ([dagger]) database.

Methods: Between June 2010 and June 2015, hepatitis B e antigen (HBeAg)-positive patients (n = 162) received Peg-IFN for 48 weeks (mono-treatment group, n = 81) and entecavir (ETV) for 12 weeks with a 48-week course of Peg-IFN starting at week 5 of ETV therapy (sequential treatment group, n = 81).

Yvan Hutin, M.D., Ph.D., from the World Health Organization in Geneva, and colleagues examined the patent and licensing status of entecavir and tenofovir using the Medicines Patent Pool MedsPaL database.

M2 PHARMA-June 27, 2018-CASI Pharma and Yiling Wanzhou Pharma Partnership to Manufacture Entecavir And Cilostazol

for the manufacturing of entecavir and cilostazol.<br />Yiling Wanzhou International Pharmaceutical Co., Ltd.

M2 EQUITYBITES-March 28, 2018-Breckenridge Pharmaceutical wins final US FDA approval for Entecavir tablets (Baraclude) ANDA for hepatitis B infection

All the patients were treated with entecavir (0.5 mg/day), and no problems were encountered.

Although nearly two-thirds of patients developed HBV reactivation, less than 5% developed alanine aminotransferase rises at least twice the upper limit of normal, and only one patient had symptomatic HBV reactivation, which entecavir therapy resolved.